Greg Slabodkin

The Biden administration on Thursday touted discounts of up to 79%, but many of these first 10 drugs are already sold well below list price.

For the Biden-Harris Administration to compare the newly announced negotiated Medicare prices to the list prices for these drugs is, at best, not very meaningful. At worst, it's disingenuous.

Last week, the Biden administration revealed the first drug prices negotiated under the Inflation Reduction Act; Lykos, Grail and others make substantial staffing cuts, and Pfizer/BioNTech see mixed results for their COVID/flu vaccine.

Project 2025, a blueprint for a potential second Trump term that highlights the IRA as a potential target, took a starring role in this week's Democratic National Convention.

Well-financed startup Tome is winding down operations just as two new companies, Borealis Biosciences and GondolaBio, are launching. Meanwhile, in the midst of already tense relations with China, House lawmakers raise the alarm about U.S. companies working with the the country's military on trials.

Congress, the Federal Trade Commission and the U.S. Patent and Trademark Office are all targeting Big Pharma’s practice of filing multiple, overlapping patents that stifle generic and biosimilar competition.

Eli Lilly this week announced plans to sell single-dose vials of its weight loss drug Zepbound directly to consumers. Novo Nordisk could adopt a similar strategy for Wegovy as its CEO is set to testify Sept. 24 before the Senate health committee.

Roche's fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi's tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two late-stage relapsing MS studies.

BioMarin’s new business strategy leaves investors with questions; Lykos CEO steps down; Terns releases compelling data on oral weight loss candidate; and more.

It's time for Congress to step up and fund America's supply chain independence from Chinese companies by bolstering our domestic manufacturing capabilities.